GUTS · Fractyl Health, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on GUTS. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About GUTS · Fractyl Health, Inc.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Live Quote
SELL (score -3) · 12-1 mom -45.9% · RSI 53.7 · above_50_only · -65.1% from high
Targets blend Wall Street consensus (5 analysts: low $2.00 / mean $5.24 / high $8.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
The dossier flags a going-concern disclosure and accelerating cash burn with runway only into early 2027, creating a severe dilution and bankruptcy risk that overrides the clinical catalyst upside. As a pre-revenue small-cap biotech with a hard anti-signal gate and no earnings or positive quality metrics, it fails the publish threshold.
The dossier flags a going-concern disclosure and accelerating cash burn with runway only into early 2027, creating a severe dilution and bankruptcy risk that overrides the clinical catalyst upside. As a pre-revenue small-cap biotech with a hard anti-signal gate and no earnings or positive quality metrics, it fails the publish threshold.
Fractyl Health is a clinical-stage metabolic biotech (obesity/T2D) with two programs: Revita DMR (endoscopic duodenal mucosal resurfacing for post-GLP-1 weight maintenance) and Rejuva gene therapy (pancreatic GLP-1 expression). The investigation was triggered by 6 Form 4 filings in the last 14 days. Of these, TWO are genuine open-market P/S buys: Director William Bradley purchased 68,493 shares at $0.7348 on June 10 ($50,329) and CFO Lara Smith Weber purchased 20,000 shares at $0.6854 on June 8 ($13,708). The remaining four filings from directors on June 10 were stock option grants (A code), not purchases — noise for the thesis. The stock trades at ~$0.72, down ~70% from its 52-week high of $2.37 following a catastrophic January 2026 dilution event and poor mid-cohort REMAIN-1 data. Near-term catalysts include REVEAL-1 one-year open-label readout (June 4, 2026 — strong: 78% weight loss retention at one year), Q3 2026 REMAIN-1 Midpoint Cohort topline, early Q4 2026 REMAIN-1 Pivotal Cohort six-month data, and a potential late-Q4 2026 FDA De Novo submission. Cash runway extends into early 2027 per management, but the company flagged going-concern risk in its 10-Q.